Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
  • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
  • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
  • A61K2800/52—Stabilizers
  • A61K2800/522—Antioxidants; Radical scavengers

Definitions

• the present invention relates to a personal care composition
• a personal care composition comprising a carboxymethyl cysteine compound and coffee seed oil.
• such composition is capable of providing synergistic antioxidation effect.
• Oxidative stress may affect our skin in many ways including signs of premature aging such as wrinkles, fine lines, uneven skin tone.
• TXNRD1 Thioredoxin reductase 1
• TXNRD1 is an oxidoreductase encoded by the TXNRD1 gene in humans and a member of the antioxidant thioredoxin system.
• TXNRD1 plays an important role in oxidative stress control. It reduces and activates thioredoxin, an oxidoreductase containing a dithiol-disulfide active site. Thioredoxin binds ROS before they can harm cells and thus protects cells against oxidative stress.
• the present inventors have recognized there is a need to develop a personal care composition which is capable of improving the gene expression of TXNRD1. Therefore, the present inventors have developed a personal care composition comprising carboxymethyl cysteine compound and coffee seed oil. It was surprisingly found that by combining carboxymethyl cysteine compound with coffee seed oil with weight ratio of the carboxymethyl cysteine compound to the coffee seed oil being 1 :200 to 12:1 , the expression of TXNRD1 gene is synergistically elevated.
• the present invention is directed to a personal care composition comprising carboxymethyl cysteine compound and coffee seed oil, wherein the weight ratio of the carboxymethyl cysteine compound to the coffee seed oil is 1 :200 to 12:1.
• the present invention is directed to a method for providing antioxidation, and/or anti-aging benefit; reducing oxidative stress; and/or upregulating the expression of thioredoxin reductase 1 gene, comprising a step of topically applying to the skin the composition of the present invention.
• the present invention is directed to use of the composition of the present invention for providing antioxidation and/or anti-aging benefit; reducing oxidative stress; and/or upregulating the expression of thioredoxin reductase 1 gene.
• the carboxymethyl cysteine compound refers to compound selected from carboxymethyl cysteine, salt of carboxymethyl cysteine, ester of carboxymethyl cysteine, amide of carboxymethyl cysteine or a mixture thereof.
• the carboxymethyl cysteine compound comprises carboxymethyl cysteine, ester of carboxymethyl cysteine, and/or salt of carboxymethyl cysteine. More preferably, the carboxymethyl cysteine compound comprises carboxymethyl cysteine, and/or salt of carboxymethyl cysteine.
• carboxymethyl cysteine compound comprises salt of carboxymethyl cysteine. Still even more preferably the carboxymethyl cysteine compound comprises lysine carboxymethyl cysteinate and most preferably, the carboxymethyl cysteine compound is lysine carboxymethyl cysteinate.
• the carboxymethyl cysteine compound is present in amount of at least 0.00001%, more preferably at least 0.0001 %, even more preferably at least 0.001 %, still even more preferably at least 0.01%, and most preferably at least 0.1 % by weight of the composition.
• the carboxymethyl cysteine compound is present in amount of no greater than 10%, more preferably no greater than 5%, even more preferably no greater than 3%, still even more preferably no greater than 1 %, and most preferably no greater than 0.5% by weight of the composition.
• the lysine carboxymethyl cysteinate is present in amount of no greater than 10%, more preferably no greater than 5%, even more preferably no greater than 3%, still even more preferably no greater than 1 %, and most preferably no greater than 0.5% by weight of the composition.
• the lysine carboxymethyl cysteinate is present in amount of at least 0.00001%, more preferably at least 0.0001 %, even more preferably at least 0.001%, still even more preferably at least 0.01 %, and most preferably at least 0.1% by weight of the composition.
• Coffee seed oil is the oil extracted from the beans of certain Coffea species. It can be extracted from unroasted coffee beans or roasted coffee beans. Coffee seed oil is rich in saturated fatty acids, unsaturated fatty acids and tocopherols. Due to these properties, coffee seed oil is sometimes used in skin care products.
• the composition of coffee seed oil varies according to the process of manufacture and Coffea species. For example, unroasted coffee seed oil may contain higher level of fatty acids, vitamins and caffeine.
• Koffee’UPTM from Givaudan, is oil of roasted Coffea arabica seeds. It is manufactured from drying spent coffee grounds followed by supercritical CO2 extraction. Koffee’UPTM is claimed to protect the skin and help the skin to stay hydrated.
• the composition of the present invention comprises coffee seed oil.
• the coffee seed oil is extracted from roasted seeds of coffee, more preferably from roasted seeds of coffee selected from coffea arabica, coffea canephora and coffea liberie, and most preferably from roasted seeds of coffee from coffea arabica.
• the coffee seed oil is obtained by supercritical fluid extraction, more preferably supercritical CO2 extraction.
• the coffee seed oil is employed in the composition in an amount of 0.00001 to 5% by weight of the composition, more preferably in an amount of 0.0001 to 2%, even more preferably from 0.005 to 0.5% and most preferably in an amount of 0.02 to 0.2% by weight of the composition.
• the weight ratio of the carboxymethyl cysteine compound to the coffee seed oil is 1 :200 to 12:1 , more preferably 1 :50 to 12:1 , even more preferably 1 :12 to 3:1 , still even more preferably 1 :6 to 1.5:1 , and most preferably 4:1 to 1 :1.
• the amount of extract in the present invention refers to the amount of extracted ingredients from the plant, excluding the weight of the extract solvent.
• the composition comprises Vitamin B3 compounds (including derivatives of vitamin B3).
• the vitamin B3 compounds comprises niacin, nicotinic acid, niacinamide or a mixture thereof.
• the most preferred vitamin B3 compound is niacinamide.
• Amount of Vitamin B3 compounds may be 0.1 to 10%, preferably 0.5 to 5% by weight of the composition.
• the composition comprises a glutamate source selected from the group consisting of glutamine, glutamine ester, glutamic acid, pyroglutamic acid, salts, and mixtures thereof. More preferably, the composition comprises pyroglutamic acid and/or salt of pyroglutamic acid. Even more preferably, the composition comprises sodium salt of pyroglutamic acid.
• the glutamate source is present in amount of 0.0001 to 10% by weight of the composition, more preferably 0.001 to 6%, even more preferably 0.01 to 3% by weight of the composition.
• the composition may optionally comprise whitening pigment.
• Whitening pigments are typically particles of high refractive index materials.
• the whitening pigment may have a refractive index of greater than 1.3, more preferably greater than 1.8 and most preferably from 2.0 to 2.7.
• Examples of such whitening pigment are those comprising bismuth oxy-chloride, boron nitride, barium sulfate, mica, silica, titanium dioxide, zirconium oxide, aluminium oxide, zinc oxide or combinations thereof. More preferred whitening pigment are particles comprising titanium dioxide, zinc oxide, zirconium oxide, mica, iron oxide or a combination thereof.
• Even more preferred whitening pigment are particles comprising zinc oxide, zirconium oxide, titanium dioxide or a combination thereof as these materials have especially high refractive index. Still even more preferably the whitening pigment is selected from titanium dioxide, zinc oxide or a mixture thereof and most preferred whitening pigment is titanium dioxide.
• the average diameter of whitening pigment is typical from 15 nm to 1 micron, more preferably from 35 nm to 800 nm, even more preferably from 50 nm to 500 nm and still even more preferably from 100 to 300 nm.
• Amount of whitening pigment may be 0.1 to 15%, preferably 0.5 to 5% by weight of the composition.
• the composition comprises polyhydric alcohol.
• Polyhydric alcohols may be selected from group of glycerin, propylyene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1 ,3-butylene glycol, isoprene glycol, ethoxylated glycerol, propoxylated glycerol or a mixture thereof.
• Most preferred polyhydric alcohol is glycerol known also as glycerin.
• the amount of polyhydric alcohol may range anywhere from 0.1 to 20%, preferably 0.5 to 15% and more preferably 2 and 10% by weight of the composition.
• Illustrative triglycerides but not limiting are sunflower seed oil, cotton oil, canola oil, soybean oil, castor oil, borage oil, olive oil, shea butter, jojoba oil and mixtures thereof. Mono- and di- glycerides may also be useful. Particularly preferable are glyceryl monostearate and glyceryl distearate.
• the composition comprises moisturizing agents.
• moisturizing agents includes, petrolatum, aquaporin manipulating actives, oat kernel flour, substituted urea like hydroxyethyl urea, hyaluronic acid and/or its precursor N-acetyl glucosamine, hyaluronic acid and/or its precursor N-acetyl glucosamine, or a mixture thereof.
• compositions may include thickeners. These may be selected from cellulosics, natural gums and acrylic polymers but not limited by this thickening agent types.
• cellulosics sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose and combinations thereof.
• Suitable gums include xanthan, pectin, karaya, agar, alginate gums and combinations thereof.
• acrylic thickeners are homopolymers and copolymers of acrylic and methacrylic acids including carbomers such as Carbopol 1382, Carbopol 982, llltrez, Aqua SF-1 and Aqua SF-2 available from the Lubrizol Corporation.
• Amounts of thickener may range from 0.01 to 3% by weight of the active polymer (outside of solvent or water) in the compositions.
• compositions of the invention may further include 0.5 to 10% by weight of sequestering agents, such as tetra sodium ethylenediaminetetraacetate (EDTA), EHDP or mixtures; opacifiers and pearlizers such as ethylene glycol distearate, titanium dioxide or Lytron 621 (Styrene/Acrylate copolymer); all of which are useful in enhancing the appearance or properties of the product.
• sequestering agents such as tetra sodium ethylenediaminetetraacetate (EDTA), EHDP or mixtures
• opacifiers and pearlizers such as ethylene glycol distearate, titanium dioxide or Lytron 621 (Styrene/Acrylate copolymer); all of which are useful in enhancing the appearance or properties of the product.
• the composition may comprise water in amount of 10 to 96% by weight of the composition, more preferably from 25 to 92%, even more preferably from 42 to 88%, most preferably from 55 to 82% by weight of the composition.
• the composition has a viscosity of at least 10 mPa s, more preferably in the range 30 to 10000 mPa s, even more preferably 50 to 5000 mPa s, and most preferably 100 to 2000 mPa s, when measured at 20 degrees C at a relatively high shear rate of about 20 s -1 .
• the composition is an emulsion, more preferably an oil-in-water emulsion.
• the composition is a fluid liquid at 25 °C and atmospheric pressure.
• the personal care composition is a skin care composition.
• Skin care composition refers to a composition suitable for topical application to human skin, including leave-on and wash-off products but preferably leave-on compositions.
• leave-on as used with reference to compositions herein means a composition that is applied to or rubbed on the skin, and left thereon.
• wash-off as used with reference to compositions herein means a skin cleanser that is applied to or rubbed on the skin and rinsed off substantially immediately subsequent to application.
• skin as used herein includes the skin on the face, neck, chest, abdomen, back, arms, under arms, hands, and legs.
• skin means includes the skin on the face and under arms, more preferably skin means skin on the face other than lips and eyelids.
• the composition is particularly preferably a moisturizer rather than a make-up product.
• the composition is a topical composition.
• the composition may be in the form of cream, lotion, ointment, solution, suspension, emulsion, paste, gel, powder, powder foundation, emulsion foundation, wax foundation, or spray. More preferably, the composition may be formulated in the form of cream, lotion, ointment, emulsion, gel, or a spray.
• the use is non-therapeutic.
• the method is non-therapeutic.
• non-therapeutic typically means for cosmetic purposes and not curative or therapeutic purposes.
• Koffee’UPTM (coffea arabica seed oil) used in the examples was obtained from Givaudan France SAS.
• the coffea arabica seed for preparing Koffee’UPTM was not obtained from India.
• This Example demonstrates the synergistic upregulation of gene expression by combining carboxymethyl cysteine compound and coffee seed oil.
• the normal human epidermal keratinocytes (NHEK, Archgene Biotechnology, Shanghai, China, Lot: NHS-2021-006) were incubated in medium together with or without actives for 24 hours. After incubation, the total RNA for each NHEK was extracted using Qiagen Mini RNeasy kit (Qiagen, Cat.74106) according to manufacturer’s protocol.
• Amplification of the gene encoding the TXNRD1 (Thioredoxin reductase 1) gene was performed with RT-PCR reagent (Universal SYBR Green Fast qPCR Mix kit (Cat. RK21203, ABclonal)) on the ABI Vii 7 Real-Time PCR Systems (Applied Biosystems, Thermo fisher scientific, Carlsbad, CA, USA).
• the Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta (YWHAZ) was selected as the housekeeping gene and all data on relative expression of the target genes was normalized to YWHAZ. The fold changes in expression were calculated relative to the blank control (medium having no active). All tests were conducted at least three times and Table 1 shows the fold changes in gene expression of TXNRD1.
• the level of the active is based on the medium. a: significantly better (p ⁇ 0.05) than either of single active at same level.
• Table 1 it was surprisingly found that the fold change when combining lysine carboxymethyl cysteinate and coffee seed oil with a specific ratio was significantly higher than the product of the fold change for lysine carboxymethyl cysteinate only and that for coffee seed oil only.
• the expression of TXNRD1 was synergistically elevated by combining lysine carboxymethyl cysteinate and coffee seed oil within the range of the present invention. In contrast, the expression of TXNRD1 gene was not elevated when combining lysine carboxymethyl cysteinate and coffee seed oil outside the range of the present invention.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Birds (AREA)
• Epidemiology (AREA)
• Dermatology (AREA)
• Gerontology & Geriatric Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Cosmetics (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=88466709

Family Applications (1)

Country Status (5)

Family Cites Families (2)

• 2023
  • 2023-10-16 JP JP2025526426A patent/JP2025535576A/ja active Pending
  • 2023-10-16 EP EP23790589.8A patent/EP4615403A1/de active Pending
  • 2023-10-16 WO PCT/EP2023/078586 patent/WO2024099688A1/en not_active Ceased
  • 2023-10-16 CN CN202380077818.0A patent/CN120187402A/zh active Pending
• 2025
  • 2025-05-06 MX MX2025005282A patent/MX2025005282A/es unknown

Also Published As

Similar Documents

Legal Events